期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2021
卷号：118
期号：8
页码：1
DOI：10.1073/pnas.2024937118
出版社：The National Academy of Sciences of the United States of America
摘要：Ma and Wang (1) tested our recently reported severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) noncovalent inhibitors (2) using their in vitro assays, and they obtained negligible or much lower inhibitory activities compared to ours. Knowing the discrepancy, we first carefully rechecked our original experimental records, and we did not find any potential concern with our data that had been repeated by multiple coauthors. Notably, the fluorescence resonance energy transfer (FRET)-based enzymatic assay used by Ma and Wang (1) is different from our FRET-based enzymatic assay in the Mpro protein (discussed below) and the FRET substrate [longer than the more popularly used substrate (3, 4) utilized in our assay].
